Equities

Gilead Sciences Inc

0QYQ:LSE

Gilead Sciences Inc

  • Price (USD)150.70
  • Today's Change2.70 / 1.82%
  • Shares traded5.04k
  • 1 Year change51.03%
  • Beta0.3741
Data delayed at least 20 minutes, as of Feb 06 2026 19:14 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Gilead Sciences Inc had net income fall -91.54% from 5.66bn to 479.00m despite a 6.04% increase in revenues from 27.12bn to 28.75bn. An increase in the selling, general and administrative costs as a percentage of sales from 20.42% to 20.63% was a component in the falling net income despite rising revenues.
Gross margin78.72%
Net profit margin27.88%
Operating margin36.06%
Return on assets14.35%
Return on equity40.54%
Return on investment18.18%
More ▼

Cash flow in USDView more

In 2024, Gilead Sciences Inc increased its cash reserves by 64.19%, or 3.91bn. The company earned 10.83bn from its operations for a Cash Flow Margin of 37.66%. In addition the company used 3.45bn on investing activities and also paid 3.43bn in financing cash flows.
Cash flow per share8.62
Price/Cash flow per share17.40
Book value per share17.34
Tangible book value per share-3.82
More ▼

Balance sheet in USDView more

Gilead Sciences Inc has a Debt to Total Capital ratio of 53.76%, a lower figure than the previous year's 116.04%.
Current ratio1.45
Quick ratio1.31
Total debt/total equity1.16
Total debt/total capital0.5376
More ▼

Growth rates in USD

SmartText is unavailable
Div yield(5 year avg)3.73%
Div growth rate (5 year)4.10%
Payout ratio (TTM)48.98%
EPS growth(5 years)-38.13
EPS (TTM) vs
TTM 1 year ago		7,560.56
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.